# The Role of PET CT In Comparison To Triphasic CT in Early Follow Up of <br> Hepatocellular Carcinoma after Transarterial Chemoemoblization 

## Ohesis

## Submitted for Partial Fulfillment of the $\mathcal{M D}$ <br> Degree in Radio-Diagnosis <br> $B y$

## Hany Rafat Atyia EL -Malah

M. Sc of Radiodiagnosis

Faculty of Medicine- Ain Shams University

## Supervised by

Prof. Dr. Mounir Sobhy Guirguis

Professor of Radiodiagnosis
Faculty of Medicine- Ain Shams University

## Ass. Prof. Dr. Enas Ahmed Azzab

Ass. Professor of Radiodiagnosis
Faculty of Medicine- Ain Shams University
Ass. Prof. Dr. Waleed Hetta
Ass. Professor of Radiodiagnosis
Faculty of Medicine- Ain Shams University
Faculty of Medicine
Ain Shams University

## Acknowledqument

2. First and foremost, my deep gratefulness and indebtedness is to Allah, the Gost Gracious and the OHost OCerciful.
3. I wish to express $m y$ deep gratitude and respect to Drof. Dr. SYounir Sobhy Guirguis Professor of Radiodiagnosis, Faculty of Medicine, Ain Shams University, for his valuable advices, continuous encouragement, judicious guidance and kind support at this study.
4. T would like to express my great thanks to Ass. Drof. Dr Conas Afrmed Azeab Ass. Professor of Radiodiagnosis, Faculty of OCedicine, Ain Shams Ziniversity, for her patience, sincere advice and kind support all through this study.
5. Special thanks are due to Ass. Drof. Dr GWaleed Fretta Ass. Drofessor of Radiodiagnosis Faculty of Medicine, Ain Shams University for his sincere efforts and fruitful encouragement.
6. I would also like to thank all $m y$ collegues who extended to me a helping fand for this work.
7. Gastly and not least, I send $m y$ deepest love to $m y$ parents, wife and $m y$ daughter THabiba for their care and ever [asting support.

## 29 Hany Rafat Atyia TET-OMalah

## List of Contents

obitle Page
List of Abbreviations ..... I
List of Tables ..... IV
List of Figures ..... V
Illustrated Cases ..... VIII
Introduction ..... 1
Aim of the work ..... 4
Review of literature
Radiological anatomy of the liver ..... 5
Pathological considerations ..... 15
Technique of PET CT and Triphasic CT ..... 24
Role of PET CT and Triphasic CT in the early follow up
of HCC after transarterial chemoembolization ..... 44
Patients and methods ..... 52
Results ..... 61
Illustrative cases ..... 68
Discussion ..... 86
Summary and conclusion ..... 96
References ..... 99
Arabic summary

## List of Abbreviation

| AFP | Alpha-fetoprotein |
| :--- | :--- |
| BGO | Bismuth germanate |
| CBD | Common bile duct |
| CECT | Contrast enhanced computed tomography |
| CHA | Common hepatic artery |
| CHD | Common hepatic duct |
| CT | Computed tomography. <br> correction |
| CTAC | European Association for the Study of the <br> Liver |
| EASL | Fluorodeoxyglucose |
| FDG | Gall bladder. |
| GB | Gastroduodenal artery |
| GDA | Glucose transporter |
| GLUT | Gadolinium oxyorthosilicate |
| GSO | Hepatocellular carcinoma |
| HCC | Hepatitis C virus |
| HCV | Hexokinase enzyme |
| HK enzyme | Inferior vena cava |
| IMV | IVferior mesenteric vein |
| kBq | Kolobecquerel |


| Kev | Kiloelectron volt |
| :--- | :--- |
| Kg | Kilogram |
| LGA | Left gastric artery |
| LHA | Left hepatic artery |
| LHV | Left hepatic vein |
| LPV | Left portal vein |
| LSECs | Liver sinusoidal endothelial cells |
| LSO | Lutetium oxyorthosilicate |
| mCi | Millicurie |
| MHV | Middle hepatic vein |
| MIP | Maximum intensity projection |
| MPV | Main portal vein |
| mRECIST | Modified Response Evaluation Criteria in <br> Solid Tumors |
| MRI | Magnetic Resonance imaging |
| N/C ratio | Nuclear/cytoplasmic ratio |
| Nal | Sodium iodide |
| NASH | Nonalcoholic steatohepatitis |
| PET | Positron Emission Tomography |
| PMT | Photomultiplier tube |
| PV | Portal vein |
| PVTT | Portal vein tumoral thrombosis |
| RAPV | Right anterior portal vein |
| RECIST | Response Evaluation Criteria in Solid |


|  | Tumors |
| :--- | :--- |
| RFA | Radiofrequency ablation |
| RHA | Right hepatic artery |
| ROI | Region of interest |
| RPPV | Right portal vein |
| RPV | Splenic artery |
| RRA | Superior mesenteric artery |
| SA | Superior mesenteric vein |
| SMA | Standardized uptake value |
| SMV | Transarterial chemoembolization product diameters |
| SPD | World Health Organization |
| SUV | TACE |
| WHO | 18- fluorodeoxyglucose |
| $\mathbf{1 8 - ~ F D G ~}$ |  |

## List of Tables

| Table <br> No. | Title | Page |
| :---: | :--- | :---: |
| 2.1 | Okuda staging system | 19 |
| 2.2 | American Joint Committee on Cancer/ TNM <br> $7^{\text {th }}$ edition | 20 |
| 3.1 | Physical properties of different scintillators <br> for positron emission tomography (PET) | 30 |
| 4.1 | World Health Organization (WHO) Criteria | 47 |
| 4.2 | Response Evaluation Criteria in Solid <br> Tumors | 48 |
| 4.3 | Modified Response Evaluation Criteria in <br> Solid Tumors (mRECIST) | 49 |
| 6.1 | Statistical data analysis including sex and <br> age. | 61 |
| 6.2 | Statistical data analysis of hepatic segmental <br> distribution and size of the <br> chemo-emoblized lesions. | 62 |
| 6.3 | Sites of extra hepatic spread. |  |
| 6.4 | Statistical data analysis of SUV max and <br> TSUV max / L SUV max. | 65 |
| 6.5 | Illustrating the Diagnostic Value of FDG <br> PET/CT and Triphasic CT in post TACE <br> follow up. | 66 |

## List of Figures

| Figures <br> No. | Title | Page |
| :---: | :--- | :---: |
| 1.1 | Anatomy of the liver segments. | 5 |
| 1.2 | Cross sectional anatomy of the liver <br> segments. | 6 |
| 1.3 | Radiographic segmental anatomy of the <br> liver. | 7 |
| 1.4 | Normal hepatic arterial anatomy. Axial <br> MIP image shows the normal anatomy of <br> the hepatic artery. CHA common hepatic <br> artery. | 9 |
| 1.5 | 3D reconstruction CT angiography on <br> upper abdominal aorta. | 9 |
| 1.6 | Normal portal venous Image from 3D CT <br> portography shows the portal vein (PV) <br> branching into the left portal vein (LPV) <br> and right portal vein (RPV). | 11 |
| 1.7 | Hepatic venous confluence. Coronal MIP <br> image from multidetector CT shows the <br> confluence of the left hepatic vein (LHV). | 12 |
| 1.8 | Normal biliary tree anatomy on MRCP. | 14 |
| 3.1 | Uptake of FDG. FDG is a glucose analog <br> that is taken up by metabolically active <br> cells by means of facilitated transport via <br> glucose transporters (Glut) in the cell <br> membrane. | 26 |


| Figures <br> No. | Title | Page |
| :---: | :---: | :---: |
| 3.2 | Annihilation reaction positrons annihilate with electrons, releasing two coincidence 511-keV photons, which are detected by scintillation crystals (blue rectangles). | 28 |
| 3.3 | A schematic of a current PET-CT scanner design. The dimensions of the gantry are 228 cm wide, 200 cm high and 168 cm deep. | 32 |
| 3.4 | Current commercial PET/CT scanners from 3 vendors. | 32 |
| 3.5 | Axial PET CT images showing physiological symmetrical uptake in the nasopharyngeal tonsils. | 37 |
| 3.6 | Symmetrical uptake is noted in the neck, supraclavicular fossa and paravertebral regions consistent with typical appearance of brown fat activity (black arrow). | 40 |
| 3.7 | (A) 58-y-old man with colon cancer. Lesion at dome of liver is mislocalized to right lung (arrow) because of respiratory motion (B) Image without attenuation correction shows that all lesions are confined to liver. | 42 |


| Figures <br> No. | Title | Page |
| :---: | :--- | :---: |
| 4.1 | a-d Representative case of rim-shaped <br> FDG uptake. A63-year-old women who <br> had hepatocellular carcinoma (HCC) in <br> segment 8 received radiofrequency <br> ablation (RFA) treatment. | 46 |
| 4.2 | Different imaging response criteria used in <br> evaluation of hepatocellular carcinoma <br> (HCC) after treatment. | 49 |
| 6.1 | Pie chart demonstrates the distribution of <br> cases in both sexes in our study. | 61 |
| 6.2 | Hepatic segmental location of the lesions. | 63 |
| 6.3 | Illustrating the Diagnostic Value of FDG <br> PET/CT and Triphasic CT in post TACE <br> follow up. | 67 |

## Illustrative cases

| Title | Page No. |
| :---: | :---: |
| Case 1 | 68 |
| Case 2 | 70 |
| Case 3 | 72 |
| Case 4 | 74 |
| Case 5 | 76 |
| Case 6 | 78 |
| Case 7 | 80 |
| Case 8 | 82 |
| Case 9 | 84 |

## Introduction

Hepatocellular carcinoma (HCC) represents the commonest primary hepatic tumor of adults. It is the $6^{\text {th }}$ most common tumor in the world and the third commonest cause of cancer related deaths (Dai et al., 2014).

Liver cancer represents about $11.85 \%$ of the malignancies of all GIT organs and $1.78 \%$ of the total malignancies among Egyptians (Holah et al., 2015).

HCC is caused by malignant transformation in hepatocytes due to chronic liver diseases resulting in cirrhosis (Tsurusaki et al., 2014).

From the selective treatment options of liver tumors, interventional procedures such as Trans arterial chemoembolization (TACE), has been widely used. The powerful cytotoxic effect of TACE by combined action of ischemia followed by chemoembolization of the tumor's feeding artery has been proved to result in therapeutic efficacy (Song et al., 2013).

Despite good results, this interventional procedure needs close monitoring to effectiveness of treatment because the rate of residual viable malignancy in tumors larger than 3 cm can reach 48\% (Tsurusaki et al., 2014).

Follow up of tumor response after TACE is important to determine whether the tumor is completely eradicated or additional treatment is required. Magnetic resonance imaging or computed tomography has been widely used for the assessment of treatment response after TACE. The determination of treatment response using size criteria, based on the Response Evaluation Criteria in Solid Tumors (RECIST), does not necessarily apply well to interventional therapy in such patients, so most radiologists have relied on the presence or absence of local contrast enhancement at the treated tumor in addition to changes in tumor size (Kim et al., 2011).

The methods which are used to detect tumor viability depend on showing arterial enhancement for reporting treatment responses. However, this concept does not adequately consider the biological activity of HCC (Song et al., 2013).

Positron Emission Tomography (PET) is a noninvasive imaging tool that uses 18- fluoro-deoxy-glucose (18- FDG) as radioactive material showing difference in metabolism between tissues thus demonstrates the functional status of suspicious lesions (Saif et al., 2010).

After interventional procedures, CT or MRI at one month are routinely performed to assess for residual tumors but there has been increasing evidence that PET can detect residual tumors earlier than CT and MRI (Tsurusaki et al., 2014).

PET/CT is a new imaging tool, whose advantages are useful in clinical oncology. The combination of anatomical and functional image has been the true evolution in diagnosis (Saif et al., 2010).

So, PET/CT can be used in the assessment of hepatocelluar biological activity as an additional predictive tool (Song et al., 2013).

## Aim of the Work

The aim of this study is to emphasize the role of PET/CT in early follow up of HCC after transarterial chemoembolization in comparison to triphasic CT.

